Oncotarget

Research Papers:

Targeting the PI3K/AKT/mTOR signaling pathway as an effectively radiosensitizing strategy for treating human oral squamous cell carcinoma in vitro and in vivo

Chih-Chia Yu, Shih-Kai Hung, Hon-Yi Lin, Wen-Yen Chiou, Moon-Sing Lee, Hui-Fen Liao, Hsien-Bin Huang, Hsu-Chueh Ho and Yu-Chieh Su _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:68641-68653. https://doi.org/10.18632/oncotarget.19817

Metrics: HTML 1520 views  |   ?  


Abstract

Chih-Chia Yu1,2,*, Shih-Kai Hung2,3,*, Hon-Yi Lin2,3, Wen-Yen Chiou2,3, Moon-Sing Lee2,3, Hui-Fen Liao4, Hsien-Bin Huang1, Hsu-Chueh Ho5 and Yu-Chieh Su6,7

1Department of Life Science and Institute of Molecular Biology, National Chung Cheng University, Chia-Yi, Taiwan, R.O.C

2Department of Radiation Oncology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan, R.O.C

3School of Medicine, Tzu Chi University, Hualian, Taiwan, R.O.C

4Department of Biochemical Science and Technology, National Chiayi University, Chia-Yi, Taiwan, R.O.C

5Department of Otolaryngology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan, R.O.C

6Division of Hematology and Oncology, E-Da Hospital, Kaohsiung, Taiwan

7School of Medicine, I-Shou University, Kaohsiung, Taiwan, R.O.C

*These authors (Chih-Chia Yu and Shih-Kai Hung) contributed equally to this work

Correspondence to:

Yu-Chieh Su, email: hepatoma@gmail.com

Keywords: PI3K/mTOR pathway, radiation, radiosensitization, radioresistant, oral cancer

Received: September 23, 2016    Accepted: June 20, 2017    Published: August 02, 2017

ABSTRACT

Radiation therapy (RT) is the current standard adjuvant approach for oral squamous cell carcinoma (OSCC) patients. Radioresistance is a major contributor to radiotherapy failure. In this study, we used patient-derived cells and a radiation-resistant cell line in vitro and in vivo for two purposes: evaluate the anti-tumor effects and understand the mechanisms in the dual PI3K/mTOR signaling pathway regulation of radiosensitization. Our findings indicate that in OML1-R cells, the radioresistance phenotype is associated with activation of the PI3K/AKT/mTOR signaling pathway. Compared to a combination of PI3K or mTOR inhibitors and radiation, dual blockade of the PI3K and mTOR kinases significantly improved radiation efficacy in oral cancer and patient-derived OSCC cells. Dual PI3K/mTOR inhibition enhanced the effect of radiation by inhibiting AKT/mTOR signaling pathways and caused G1 phase arrest, which is associated with downregulation of cyclin D1/CDK4 activity, leading to growth inhibition. In nude mice xenografted with radioresistant OML1-R cells, the combined treatment was also more effective than RT alone in reducing tumor growth. This treatment was also demonstrated to be dependent on the inhibition of protein kinase-dependent S6 kinase pathway and eIF4E-mediated cap-dependent translation. These findings indicate that activation of the PI3K/AKT/mTOR signaling pathway has a role in radioresistance of OSCC. We determined that a PI3K/mTOR inhibitor combined with radiation exhibits synergistic inhibition of the AKT/mTOR axis and induces cell cycle arrest. Our results show the therapeutic potential of drugs targeting the PI3K/AKT/mTOR signaling pathway should be new candidate drugs for radiosensitization in radiotherapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 19817